Literature DB >> 23089757

Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.

Julien Bador1, Lucie Amoureux, Emmanuel Blanc, Catherine Neuwirth.   

Abstract

Achromobacter xylosoxidans is an innately multidrug-resistant pathogen which is emerging in cystic fibrosis (CF) patients. We characterized a new resistance-nodulation-cell division (RND)-type multidrug efflux pump, AxyXY-OprZ. This system is responsible for the intrinsic high-level resistance of A. xylosoxidans to aminoglycosides (tobramycin, amikacin, and gentamicin). Furthermore, it can extrude cefepime, carbapenems, some fluoroquinolones, tetracyclines, and erythromycin. Some of the AxyXY-OprZ substrates are major components widely used to treat pulmonary infections in CF patients.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23089757      PMCID： PMC3535963          DOI： 10.1128/AAC.01243-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment.

Authors:  Winnie Ridderberg; Karen E M Bendstrup; Hanne V Olesen; Søren Jensen-Fangel; Niels Nørskov-Lauritsen
Journal:  J Cyst Fibros       Date:  2011-08-10       Impact factor: 5.482

2.  Primary mechanisms mediating aminoglycoside resistance in the multidrug-resistant Pseudomonas aeruginosa clinical isolate PA7.

Authors:  Yuji Morita; Junko Tomida; Yoshiaki Kawamura
Journal:  Microbiology       Date:  2012-01-27       Impact factor: 2.777

3.  In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods.

Authors:  Marisa Almuzara; Adriana Limansky; Viviana Ballerini; Laura Galanternik; Angela Famiglietti; Carlos Vay
Journal:  Int J Antimicrob Agents       Date:  2009-11-04       Impact factor: 5.283

4.  First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.

Authors:  Julien Bador; Lucie Amoureux; Jean-Marie Duez; Anthony Drabowicz; Eliane Siebor; Catherine Llanes; Catherine Neuwirth
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

5.  A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa.

Authors:  Cédric Muller; Patrick Plésiat; Katy Jeannot
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

6.  Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei.

Authors:  R A Moore; D DeShazer; S Reckseidler; A Weissman; D E Woods
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

7.  Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.

Authors:  C R Hansen; T Pressler; K G Nielsen; P Ø Jensen; T Bjarnsholt; N Høiby
Journal:  J Cyst Fibros       Date:  2009-11-25       Impact factor: 5.482

8.  Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases.

Authors:  Daniel Tena; Alejandro González-Praetorius; Mercedes Pérez-Balsalobre; Oliva Sancho; Julia Bisquert
Journal:  Scand J Infect Dis       Date:  2008

9.  Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.

Authors:  Samiya Razvi; Lynne Quittell; Ase Sewall; Hebe Quinton; Bruce Marshall; Lisa Saiman
Journal:  Chest       Date:  2009-06-08       Impact factor: 9.410

10.  Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa.

Authors:  T Mine; Y Morita; A Kataoka; T Mizushima; T Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
View more
  37 in total

1.  AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand.

Authors:  Pisut Pongchaikul; Pitak Santanirand; Svetlana Antonyuk; Craig Winstanley; Alistair C Darby
Journal:  FEMS Microbiol Lett       Date:  2020-07-01       Impact factor: 2.742

Review 2.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

3.  Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin.

Authors:  Julien Bador; Catherine Neuwirth; Nadège Grangier; Marie Muniz; Leslie Germé; Jérémy Bonnet; Vignesh-Guru Pillay; Catherine Llanes; Claire de Curraize; Lucie Amoureux
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

4.  Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans.

Authors:  Yongfei Hu; Yuying Zhu; Yanan Ma; Fei Liu; Na Lu; Xi Yang; Chunguang Luan; Yong Yi; Baoli Zhu
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

5.  Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.

Authors:  Laura Barrado; Patricia Brañas; M Ángeles Orellana; M Teresa Martínez; Gloria García; Joaquín R Otero; Fernando Chaves
Journal:  J Clin Microbiol       Date:  2013-03-27       Impact factor: 5.948

6.  Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.

Authors:  Sean K Tom; Yvonne C W Yau; Trevor Beaudoin; John J LiPuma; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

7.  Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.

Authors:  Lucie Amoureux; Julien Bador; Sakina Fardeheb; Cédric Mabille; Charlyne Couchot; Clémence Massip; Anne-Lise Salignon; Guillaume Berlie; Véronique Varin; Catherine Neuwirth
Journal:  Appl Environ Microbiol       Date:  2013-09-13       Impact factor: 4.792

Review 8.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

9.  Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Achromobacter Species from Cystic Fibrosis Patients.

Authors:  Ijeoma N Okoliegbe; Karolin Hijazi; Kim Cooper; Corinne Ironside; Ian M Gould
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  Interaction of ArmZ with the DNA-binding domain of MexZ induces expression of mexXY multidrug efflux pump genes and antimicrobial resistance in Pseudomonas aeruginosa.

Authors:  Adam Kawalek; Magdalena Modrzejewska; Bartlomiej Zieniuk; Aneta Agnieszka Bartosik; Grazyna Jagura-Burdzy
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.